Evaluate

September 21, 2018

Oncolytics prepares to tap US investors

The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.

September 13, 2018

Another must-have oncolytic virus asset for big pharma

Boehringer Ingelheim struck a deal with the oncolytic virus company Viratherapeutics in 2016, and it has clearly seen something extraordinary in the intervening two…

February 21, 2018

Merck & Co makes biggest oncolytic virus bet since Amgen in 2011

December 13, 2016

Setbacks fail to stifle oncolytic virus business development

December 08, 2016

Ash winners and losers – Bluebird and Juno set the pulses racing

October 05, 2016

Interview – Boehringer beats a brave route with oncolytic virus deal

April 30, 2015

Adcom puts T-Vec on track to underwhelm

October 06, 2014

Acquisitions help define performance of mid and small cap stocks

September 22, 2014

Still unpartnered, but now worth a lot more